Fig. 1From: Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapyHVEM binding network regulates immune homeostasis. Activation of BTLA signaling leads to the recruitment of SHP-1/2 and negatively regulates T cell responses, whereas GRB-2 promotes survival through the AKT pathway. HVEM-mediated NF-κB signaling leads to enhanced activation status, inflammation, and survivalBack to article page